

Conti-Fine, B.M.

Examiner:

Filed:

Title:

08/991,143

Group Art Unit: 1643 Docket: 600.423US1

December 16, 1997 METHOD TO TREAT UNDESIRABLE IMMUNE RESPONSES

## **COMMUNICATION UNDER 37 CFR § 1.821**

**BOX SEQUENCE** Assistant Commissioner for Patents Washington, D.C. 20231

FJUN 2

Sir:

In response to the "Notice to File Missing Parts of Application" dated March 16, 1998 (copy enclosed), a SEQUENCE LISTING, to conform the above-referenced application to the requirements of §1.821 through §1.825, is submitted herewith.

Applicants submit herewith a SEQUENCE LISTING to conform the abovereferenced application to the requirements of §1.821 through §1.825.

In accordance with Rule 1.821(e), a copy of the above-submitted SEQUENCE LISTING in ASCII computer readable form is also submitted herewith. It is respectfully submitted that the contents of the paper version of the SEQUENCE LISTING and the computer readable form being submitted herewith are the same.

It is further submitted that the paper copy of the SEQUENCE LISTING and the computer readable form of the SEQUENCE LISTING do not represent new matter.

If necessary, please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

Respectfully submitted,

By Applicants' attorneys,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A. P.O. Box 2938 Minneapolis, MN 55402 (612) 339-0331

Date:	8 June	1	9	98	
Daic.	$^{\prime\prime}$	•	٠.		

By: Woer Warren D. Woessner Reg. No. 30,440

Signature

Name

Application No.: 08

	NOTICE TO COURT WITH THE PROPERTY OF THE PROPE
	NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
	NUCLEOTIDE SEQUENCE ANDIOR AMINO ACID SEQUENCE DISCLOSURES
	DV-ADI. 16, 1998 & Aug. 16, 1998
	The nucleotide and/or amino acid sequence disclosure contained in this application does not
	comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for
	the following reason(s):
. مدم	1. This position to the fail to the standard of the standard o
1000	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.325. Applicant's
	attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
l =	7 10235, May 1, 1330.
-	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence
0 \$	Listing" as required by 37 C.F.R. 1.821(c).
	PACE
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by
	☐ 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. Ecwever, the
	content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.322 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	- Raw Sequence Listing.
Ŷ.	5. The computer readable form that has been filed with this application has been found to be damaged
	and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute
	computer readable form must be submitted as required by 37 C.F.R. 1.325(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the
	"Sequence Listing" as required by 37 C.F.R. 1.821(a).
	7. Other:
s.	
	Applicant Must Provide:
	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its
	entry into the specification.
	A statement that the content of the paper and computer readable copies are the same and, where
	applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.321(g) or
	1.325(b) or 1.325(d).
	Ear questions regarding compliance to the
	For questions regarding compliance to these requirements, please contact:
	For Rules Interpretation, call (703) 308-4216
	For CRF Submission Help, call (703) 308-4212
	For Patentin software help, call (703) 308-6856
	PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE